Two for the price of one : emerging carbapenemases in a returning traveller to New York City
© BMJ Publishing Group Limited [year]. No commercial re-use. See rights and permissions. Published by BMJ..
We report a case of a complex orthopaedic infection in a patient returning to New York City from Bangladesh where he was involved in a serious motor vehicle accident. He developed extensive osteomyelitis with a carbapenem-resistant Klebsiella pneumoniae The isolate was unique due to the coexistence of New Delhi metallo-β-lactamase-1 and Oxacillinase type-181 carbapenemases, which are relatively uncommon in North America and were presumably acquired in Bangladesh. Herein, we explore challenges associated with management of carbapenem-resistant Enterobacteriaceae infections, including limited available data on effective antimicrobial therapy. We also highlight the added value of rapid diagnostic technology in guiding clinical management. Ultimately, the patient required both aggressive surgical management and combination therapy with aztreonam and ceftazidime-avibactam for true source control and favourable clinical outcome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2018 |
|---|---|
| Enthalten in: |
BMJ case reports - 2018(2018) vom: 18. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mittal, Jaimie [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.11.2018 Date Revised 26.09.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bcr-2018-225440 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM286623110 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM286623110 | ||
| 003 | DE-627 | ||
| 005 | 20231225052149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bcr-2018-225440 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0955.xml |
| 035 | |a (DE-627)NLM286623110 | ||
| 035 | |a (NLM)30021742 | ||
| 035 | |a (PII)bcr-2018-225440 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mittal, Jaimie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Two for the price of one |b emerging carbapenemases in a returning traveller to New York City |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.11.2018 | ||
| 500 | |a Date Revised 26.09.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © BMJ Publishing Group Limited [year]. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a We report a case of a complex orthopaedic infection in a patient returning to New York City from Bangladesh where he was involved in a serious motor vehicle accident. He developed extensive osteomyelitis with a carbapenem-resistant Klebsiella pneumoniae The isolate was unique due to the coexistence of New Delhi metallo-β-lactamase-1 and Oxacillinase type-181 carbapenemases, which are relatively uncommon in North America and were presumably acquired in Bangladesh. Herein, we explore challenges associated with management of carbapenem-resistant Enterobacteriaceae infections, including limited available data on effective antimicrobial therapy. We also highlight the added value of rapid diagnostic technology in guiding clinical management. Ultimately, the patient required both aggressive surgical management and combination therapy with aztreonam and ceftazidime-avibactam for true source control and favourable clinical outcome | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a bone and joint infections | |
| 650 | 4 | |a infections | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Azabicyclo Compounds |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a avibactam, ceftazidime drug combination |2 NLM | |
| 650 | 7 | |a beta-Lactamase Inhibitors |2 NLM | |
| 650 | 7 | |a Ceftazidime |2 NLM | |
| 650 | 7 | |a 9M416Z9QNR |2 NLM | |
| 650 | 7 | |a Aztreonam |2 NLM | |
| 650 | 7 | |a G2B4VE5GH8 |2 NLM | |
| 700 | 1 | |a Szymczak, Wendy A |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Levi, Michael H |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Kreiswirth, Barry N |e verfasserin |4 aut | |
| 700 | 1 | |a Riska, Paul F |e verfasserin |4 aut | |
| 700 | 1 | |a Nori, Priya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ case reports |d 2008 |g 2018(2018) vom: 18. Juli |w (DE-627)NLM209291001 |x 1757-790X |7 nnns |
| 773 | 1 | 8 | |g volume:2018 |g year:2018 |g day:18 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bcr-2018-225440 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2018 |j 2018 |b 18 |c 07 | ||